NCT02688712 2026-04-13
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03206177 2024-08-07
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
University of Oklahoma
Phase 1 Completed
NCT05700656 2024-07-22
Galunisertib Combined With Capecitabine in Advanced CRC With PM
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT02672475 2023-11-22
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT04605562 2021-09-05
Umbrella Biomarker-Guided Therapy in NPC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn